ABT-418

Drugbox
IUPAC_name = 3-methyl-5- [(2S)-1-methylpyrrolidin-2-yl] -1,2-oxazole


width= 240
CAS_number= 147402-53-7
ATC_prefix=
ATC_suffix=
PubChem= 119380
DrugBank=
C=9 | H=14 | N=2 | O=1
molecular_weight = 166.22
smiles = CC1=NOC(=C1) [C@@H] 2CCCN2C
bioavailability=
metabolism =
elimination_half-life=
excretion =
pregnancy_category =
legal_status =
routes_of_administration=

ABT-418 is a drug developed by Abbott, which acts as a partial agonist at neural nicotinic acetylcholine receptors. It binds with high affinity to the α4β2, α2β2 and α7 subtypes, but not to the α3β4 subtype.cite journal | author = Papke RL, Thinschmidt JS, Moulton BA, Meyer EM, Poirier A | title = Activation and inhibition of rat neuronal nicotinic receptors by ABT-418 | journal = Br. J. Pharmacol. | volume = 120 | issue = 3 | pages = 429–38 | year = 1997 | month = February | pmid = 9031746 | pmc = 1564486 | doi = 10.1038/sj.bjp.0700930 | url = | issn = ] cite journal | author = Briggs CA, McKenna DG, Piattoni-Kaplan M | title = Human alpha 7 nicotinic acetylcholine receptor responses to novel ligands | journal = Neuropharmacology | volume = 34 | issue = 6 | pages = 583–90 | year = 1995 | month = June | pmid = 7566493 | doi = 10.1016/0028-3908(95)00028-5 | url = | issn = ] It has nootropic, neuroprotective and anxiolytic effects,cite journal | author = Arneric SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Anderson DJ, Raszkiewicz JL, Hughes ML, Cadman ED, Adams P, Garvey DS' | title = (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization | journal = J. Pharmacol. Exp. Ther. | volume = 270 | issue = 1 | pages = 310–8 | year = 1994 | month = July | pmid = 7518514 | doi = | url = http://jpet.aspetjournals.org/cgi/content/abstract/270/1/310 | issn = ] cite journal | author = Decker MW, Brioni JD, Sullivan JP, Buckley MJ, Radek RJ, Raszkiewicz JL, Kang CH, Kim DJ, Giardina WJ, Wasicak JT | title = (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization | journal = J. Pharmacol. Exp. Ther. | volume = 270 | issue = 1 | pages = 319–28 | year = 1994 | month = July | pmid = 7913497 | doi = | url = http://jpet.aspetjournals.org/cgi/content/abstract/270/1/319 | issn = ] cite journal | author = Brioni JD, O'Neill AB, Kim DJ, Buckley MJ, Decker MW, Arneric SP | title = Anxiolytic-like effects of the novel cholinergic channel activator ABT-418 | journal = J. Pharmacol. Exp. Ther. | volume = 271 | issue = 1 | pages = 353–61 | year = 1994 | month = October | pmid = 7965735 | doi = | url = http://jpet.aspetjournals.org/cgi/reprint/271/1/353 | issn = ] cite journal | author = Prendergast MA, Terry AV, Jackson WJ, "et al" | title = Improvement in accuracy of delayed recall in aged and non-aged, mature monkeys after intramuscular or transdermal administration of the CNS nicotinic receptor agonist ABT-418 | journal = Psychopharmacology (Berl.) | volume = 130 | issue = 3 | pages = 276–84 | year = 1997 | month = April | pmid = 9151363 | doi = 10.1007/s002130050240 | url = | issn = ] and has been researched for treatment of both Alzheimer's diseasecite journal | author = Potter A, Corwin J, Lang J, Piasecki M, Lenox R, Newhouse PA | title = Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease | journal = Psychopharmacology (Berl.) | volume = 142 | issue = 4 | pages = 334–42 | year = 1999 | month = March | pmid = 10229057 | doi = 10.1007/s002130050897| url = | issn = ] and more recently ADHD.cite journal | author = Wilens TE, Biederman J, Spencer TJ, Bostic J, Prince J, Monuteaux MC, Soriano J, Fine C, Abrams A, Rater M, Polisner D | title = A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder | journal = Am J Psychiatry | volume = 156 | issue = 12 | pages = 1931–7 | year = 1999 | month = December | pmid = 10588407 | doi = | url = http://ajp.psychiatryonline.org/cgi/content/abstract/156/12/1931 | issn = ] cite journal | author = Horrigan JP | title = Present and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder | journal = Expert Opin Pharmacother | volume = 2 | issue = 4 | pages = 573–86 | year = 2001 | month = April | pmid = 11336608 | doi = 10.1517/14656566.2.4.573 | url = | issn = ] cite journal | author = Spencer T, Biederman J | title = Non-stimulant treatment for Attention-Deficit/Hyperactivity Disorder | journal = J Atten Disord | volume = 6 Suppl 1 | issue = | pages = S109–19 | year = 2002 | pmid = 12685525 | doi = | url = | issn = ] ABT-418 was reasonably effective for both applications and fairly well tolerated, but produced some side effects, principally nausea, and it is unclear whether ABT-418 itself will proceed to clinical development or if another similar drug will be used instead.cite journal | author = Wilens TE, Decker MW | title = Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition | journal = Biochem. Pharmacol. | volume = 74 | issue = 8 | pages = 1212–23 | year = 2007 | month = October | pmid = 17689498 | doi = 10.1016/j.bcp.2007.07.002 | url = | issn = ]

References